Clinical and Translational Research of Hematological Malignancies
A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Clinical Medicine, Cell, and Organism Physiology".
Deadline for manuscript submissions: 10 November 2024 | Viewed by 57
Special Issue Editor
Interests: B and T cell signaling; cytokine regulation; transcription factor regulation; antibody-based therapeutics
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
I would like to welcome you to this Special Issue, “Clinical and Translational Research of Hematological Malignancies” for the Journal of Personalized Medicine (ISSN 2075-4426, https://www.mdpi.com/journal/jpm).
This Special Issue focuses on the latest developments in the field of hematological malignancies, including clinical research and the outcomes of clinical trials. Real-world experiences in patients’ responses to hematological malignancies are also the focus of this Special Issue.
Antibodies and chimeric antigen receptor-engineered T cells (CAR-T) are increasingly used for cancer immunotherapy. Small molecule inhibitors, targeting cellular oncoproteins and enzymes such as BCR-ABL, JAK2, Bruton tyrosine kinase, FLT3, BCL-2, IDH1, and IDH2, are biomarker-driven chemotherapy-free agents approved for several major hematological malignancies.
Since 2017, a number of agents have been approved for acute myeloid leukemia (AML). These included several targeted therapies like venetoclax, FLT3 inhibitors, IDH inhibitors, and others. The management of AML is complicated, highlighting the need for expertise in order to deliver optimal therapy and achieve optimal outcomes.
We invite you to submit primary research papers and review articles dealing with the above spectrum as well as topics beyond AML. We look forward to exploring with you this exciting new era in hematological malignancies.
Dr. Elaine Yee Lin Chung
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- acute myeloid leukemia (AML)
- acute lymphoblastic leukemia (ALL)
- diffuse large B-cell lymphoma (DLBCL)
- follicular lymphoma (FL)
- marginal zone lymphoma (MZL)
- mantle cell lymphoma (MCL)
- multiple myeloma (MM)
- CAR-T
- antibody–drug conjugate (ADC)
- venetoclax
- FLT3 inhibitors
- IDH inhibitors
